Dosing of Cohort 1 complete with first three patients having received starting dose of JAG201 delivered via intracerebroventricular (ICV) injectionFirst two patients in dose-escalation Cohort 2 have ...
Science’s success at staving off death from heart disease or cancer has made another diagnosis more likely: Dementia.
New research talks about a promising adjunctive treatment to help people to build a life that isn't run by OCD.
This approach supports periodontal health, delivers promising acute improvements in cardiac electrophysiology and ...
Most women experience the effects of menopause firsthand. However, the choice of treatment can be complicated, and research shows both benefits and risks.
A low-dose, single-pill combination proved to be as effective as — and in some cases, superior to — standard-dose monotherapy ...
The device is administered as a swallowable capsule that is filled with liquid by a physician and naturally leaves the body after approximately 4 months.
Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results